Welcome to our dedicated page for Akari Therapeutics Plc SEC filings (Ticker: AKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Wondering whether nomacopan hit its clinical endpoints or how much cash Akari has left to fund trials? Investors comb Akari Therapeutics filings for exactly these answers. From fresh Phase II data tucked into an 8-K to detailed R&D spend in the quarterly 10-Q, each document shapes the outlook for this orphan-disease biotech.
Stock Titan keeps every disclosure in one place and makes them readable. Our AI converts the 200-page annual report into plain language, surfaces section-by-section highlights, and links directly to the numbers you need. Searching for 鈥淎kari Therapeutics insider trading Form 4 transactions鈥� or real-time alerts on executive stock moves? We tag each Form 4 the moment it hits EDGAR and show patterns across time. Need the 鈥淎kari Therapeutics quarterly earnings report 10-Q filing鈥� or an 鈥淎kari Therapeutics proxy statement executive compensation鈥� breakdown? One click delivers AI-generated context alongside the original PDF.
- Track trial milestones via 鈥淎kari Therapeutics 8-K material events explained鈥�
- Get cash-runway metrics from the latest 鈥淎kari Therapeutics earnings report filing analysis鈥�
- Receive instant alerts on 鈥淎kari Therapeutics Form 4 insider transactions real-time鈥�
Whether you鈥檙e understanding Akari Therapeutics SEC documents with AI or need the 鈥淎kari Therapeutics annual report 10-K simplified鈥�, our platform delivers clarity. Stop downloading bulky files; start focusing on the clinical and financial signals that move AKTX.
Akari Therapeutics, Plc reported a six-month net loss of $5.6 million and a cash and restricted cash balance of $2.7 million as of June 30, 2025. The company recorded an accumulated deficit of $252.9 million and explicitly stated that its cash balance is not sufficient to fund operations for the one-year period following issuance, which management says raises substantial doubt about the Company鈥檚 ability to continue as a going concern.
In November 2024 Akari completed the acquisition of Peak Bio, recording $39.18 million of in鈥憄rocess R&D (IPR&D) and $8.43 million of goodwill tied to its ADC platform and payload PH1. During H1 2025 the company completed a March 2025 private placement with net proceeds of approximately $5.6 million and recognized a $1.2 million gain from settlement of payables. Shares outstanding increased to 65.23 billion ordinary shares at June 30, 2025, reflecting multiple financings and conversions. Subsequent events disclosed an August 2025 note purchase commitment for an aggregate purchase price of $3.0 million (aggregate principal issuable $3.8 million), expected to close in tranches.
Insider Trading Alert: Abizer Gaslightwala, President & CEO and Director of Akari Therapeutics, has increased his position through two separate purchases of American Depositary Shares (ADS):
- June 23, 2025: Acquired 943 ADS at $1.15 per share
- June 24, 2025: Acquired 5,203 ADS at weighted average price of $1.16
Following these transactions, Gaslightwala now directly owns 277,574 ADS. Each ADS represents 2,000 ordinary shares with $0.0001 par value. The insider's accumulation of shares at these price levels may signal management's confidence in the company's prospects. The Form 4 was filed within the required reporting timeframe and executed by Torsten Hombeck as Attorney-in-Fact.
Akari Therapeutics plc (NASDAQ: AKTX) 鈥� Form 4 insider transaction
On 06/20/2025, President & Chief Executive Officer Abizer Gaslightwala, who also serves as a director of the company, purchased 10,000 American Depositary Shares (ADS) of Akari Therapeutics in an open-market transaction. The shares were acquired at a price of $1.20 per ADS, for an aggregate consideration of approximately $12,000.
Following the purchase, the reporting person鈥檚 direct holding increased to 271,428 ADS. Each ADS represents 2,000 ordinary shares of Akari Therapeutics with a par value of $0.0001 per ordinary share, as noted in the footnote to the filing.
No dispositions were reported, and the filing shows no derivative security transactions. The form was signed by Torsten Hombeck, acting as attorney-in-fact, on 06/24/2025.
This Form 4 therefore documents a single, straightforward insider purchase by the company鈥檚 most senior executive, with no accompanying sales or option exercises disclosed.
Insider Purchase Alert: Abizer Gaslightwala, President & CEO and Director of Akari Therapeutics, has acquired 15,000 American Depositary Shares (ADS) at a price of $1.20 per share on June 17, 2025. Each ADS represents 2,000 ordinary shares of the company.
Following this transaction, Gaslightwala now beneficially owns 261,428 ADSs directly. This insider purchase demonstrates a significant investment by the company's top executive, potentially signaling confidence in the company's future prospects.
- Transaction Type: Direct Purchase (Form 4)
- Total Investment Value: $18,000
- Transaction Date: June 17, 2025
- Filing Date: June 28, 2025
- Ownership Form: Direct
FAQ
What is the current stock price of Akari Therapeutics Plc (AKTX)?
What is the market cap of Akari Therapeutics Plc (AKTX)?
